Black Diamond Therapeutics Inc logo

BDTX - Black Diamond Therapeutics Inc News Story

$24.75 0.1  0.5%

Last Trade - 12/04/21

Sector
Healthcare
Size
Mid Cap
Market Cap £649.3m
Enterprise Value £419.5m
Revenue £n/a
Position in Universe 2933rd / 6825

Black Diamond Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Tue 24th November, 2020 12:45pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201124:nGNX7VX52d&default-theme=true


CAMBRIDGE, Mass. and NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Black Diamond
Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company
pioneering the discovery and development of small molecule, tumor-agnostic
therapies, today announced that its President and Chief Executive Officer,
David M. Epstein, Ph.D., will present an update about the Company’s progress
at the Piper Sandler 32(nd) Annual Virtual Healthcare Conference, taking place
December 1-3, 2020.

A webcast of the presentation will be made available at the start of the
conference on the investor relations section of the Company’s website,
www.blackdiamondtherapeutics.com. A replay of the presentation will also be
available and archived on the site for three weeks.  

About Black Diamond
Black Diamond Therapeutics is a precision oncology medicine company pioneering
the discovery of small molecule, tumor-agnostic therapies. Black Diamond
targets undrugged mutations in patients with genetically defined cancers.
Black Diamond is built upon a deep understanding of cancer genetics, protein
structure and function, and medicinal chemistry. The Company’s proprietary
technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is
designed to allow Black Diamond to analyze population-level genetic sequencing
data to identify oncogenic mutations that promote cancer across tumor types,
group these mutations into families, and develop a single small molecule
therapy in a tumor-agnostic manner that targets a specific family of
mutations. Black Diamond was founded by David M. Epstein, Ph.D. and Elizabeth
Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began
building the MAP platform and chemistry discovery engine. For more
information, please visit www.blackdiamondtherapeutics.com.

Contacts:

For Investors:
Natalie Wildenradt
investors@bdtherapeutics.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtherapeutics.com


(https://www.globenewswire.com/NewsRoom/AttachmentNg/b8da4d92-789b-4f0a-a1e2-2739af370155)



GlobeNewswire, Inc. 2020
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.